Bend Bioscience Expands Gainesville Facility with Commercial-Scale Spray Dryer and Dry Granulation System

• Bend Bioscience has added a commercial-scale spray dryer and a Gerteis dry granulation system to its Gainesville, Georgia facility.

• The expansion enhances the site’s capabilities in oral solid dosage forms, bioavailability solutions, and commercial-scale production.

Bend Bioscience has announced the installation of new equipment at its 120,000-square-foot Gainesville, Georgia facility, strengthening its pharmaceutical services and manufacturing capabilities. The addition includes a GEA PSD-4 spray dryer and a Gerteis dry granulation system, which will enhance absorption and bioavailability solutions for oral dose forms.

The new spray drying suite features secondary vacuum drying systems, multiple tank sizes for flexible batch production, a dual-stage condenser for handling various solvents, and the capacity to process highly potent active pharmaceutical ingredients (APIs). The equipment is expected to arrive this month, with installation set to begin immediately to align with potential customer project timelines.

“Our FDA-inspected Gainesville site is known for its exceptional customer service, and these latest additions demonstrate our commitment to providing strong, innovative, and comprehensive solutions that empower our customers to bring their transformative therapies to market,” said Owen Murray, CEO of Bend Bioscience.

The Gainesville facility specialises in oral solid dosage forms and serves as a centre of excellence for commercial manufacturing, modified release, and multiparticulate formulations. It also provides analytical support, late-phase tech transfer, and specialist packaging. These new capabilities complement the company’s clinical development expertise in spray-dried dispersions at its Bend, Oregon site, reinforcing Bend Bioscience’s ability to support early-phase development through to commercial supply.